Breaking: FDA announces next round of priority review vouchers

Eli Lilly, Novo Nordisk, and Vertex are among the recipients.

Log In    Subscribe BREAKING NEWS   FDA announces next round of priority review vouchers By Lizzy Lawrence Adobe The FDA on Thursday announced the second batch of companies being granted a "Commissioner's National Priority Voucher," a ticket to speedier reviews of drug candidates aligned with U.S. priorities.    The announcement came as the Trump administration unveiled agreements with Eli Lilly and Novo Nordisk to reduce the prices of popular obesity drugs — part of a broader effort to show its interest in delivering medications to Americans faster, and at cheaper prices, than in the past.  READ MORE Sign up for Biotech Scorecard Unfiltered, uncompromising analysis on the biotech world. Learn more. In Case You Missed It 1   How the first nine drug companies won priority review vouchers from Marty Makary's FDA By Lizzy Lawrence 2   Under Vinay Prasad, employees at a key FDA center fear speaking out, look for the exits By Lizzy Lawrence 3   Trump announces deal with Lilly, Novo to expand access to weight loss drugs, cut prices By Daniel Payne and Elaine Chen 4   Experts worry FDA's credibility is being shredded by scandal and 'soap opera' By Matthew Herper and Lizzy Lawrence Don't miss out on another STAT investigation Unlock the world of health and medicine with a subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us